04 June 2021 : Original article
Coronavirus Disease 2019 and Kidney Transplantation in Saudi Arabia: Outcomes and Future Opportunities
Ali Alshaqaq1ABCDEF*, Abdulnaser Al Abadi1ACF, Abdulrahman Altheaby2ABF, Mohammed A. Bukhari3ABF, Basil Alnasrallah
1AB, Alaa Alamoudi4AB, Ziad Arabi2A, Fayez Alhejaili2B, Khalid Bin Saad2A, Ahmed Busbaih5B, Mohammed Abdelrahim Idris1AB, Sumayah Askandarani1AB, Meteb M. AlBugami1A, Fahad E. Alotaibe1E, Khaled Hamawi1E, Khalid Bel’eed Akkari1ACE
DOI: 10.12659/AOT.931832
Ann Transplant 2021; 26:e931832
Table 3 Treatment and clinical outcomes.
| Factors | Results (n=130) |
|---|---|
| Hydroxychloroquine | 15 (11.5%) |
| Azithromycin | 40 (30.8%) |
| Tocilizumab | 7 (5.4%) |
| Favipiravir | 26 (20%) |
| Convalescent serum or plasma | 7 (5.4%) |
| Tacrolimus adjustment | 45 (34.6%) |
| Mycophenolate adjustment | 115 (88.5%) |
| Steroid adjustment | 100 (76.9%) |
| 28 (21.5%) | |
| 11 (7.25–24) | |
| Nasal cannula | 16 (37.2%) |
| High-flow nasal cannula | 8 (18.6%) |
| Intubation/mechanical ventilation | 18 (41.9%) |
| Extracorporeal membrane oxygenation | 1 (2.3%) |
| 14 (10.8%) | |
| 35 (26.9%) | |
| 8 (6.2%) | |
| Bacterial | 29 (76.3%) |
| Fungal | 3 (7.9%) |
| Cytomegalovirus | 6 (15.8%) |
| 14 (10.8%) | |
| ** | 1 (0.77%) |
| 35 (29–44.25) | |
| * Results are expressed as mean±standard deviation, median (25–75 percentile) and number (percentage); ** censored for death. | |